Effects of hemodialysis and vitamin E supplementation on low-density lipoprotein oxidizability in end-stage renal failure

Journal of Nephrology

Volumn 26, Issue 3, 2013, Pages 549-555

  Baldi, Simona ^a   Innocenti, Maurizio ^b   Frascerra, Silvia ^a   Nannipieri, Monica ^a   Lippi, Alberto ^b   Rindi, Paolo ^b   Ferrannini, Ele ^a  

^a UNIVERSITY OF PISA   (Italy)

^b CISANELLO HOSPITAL   (Italy)

Author keywords

Hemodialysis; LDL lipid oxidation; Lipoprotein metabolism; Oxidizability; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HEMODIALYSIS; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; LIPID BLOOD LEVEL; LIPID COMPOSITION; MALE; OXIDATION; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

DIETARY SUPPLEMENTS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; RENAL DIALYSIS; VITAMIN E;

EID: 84877965938     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000190     Document Type: Article

References (31)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5)(Suppl 3):S112-S119.
2. Wanner C, Zimmermann J, Quaschning T, Galle J. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients. Kidney Int Suppl. 1997;62:S53-S55.
3. McEneny J, Loughrey CM, McNamee PT, Trimble ER, Young IS. Susceptibility of VLDL to oxidation in patients on regular haemodialysis. Atherosclerosis. 1997;129(2):215-220.
4. Panzetta O, Cominacini L, Garbin U, et al. Increased susceptibility of LDL to in vitro oxidation in patients on maintenance hemodialysis: effects of fish oil and vitamin E administration. Clin Nephrol. 1995;44(5):303-309.
5. Maggi E, Bellazzi R, Falaschi F, et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int. 1994;45(3):876-883.
6. Lazarus JM, Owen WF. Role of bioincompatibility in dialysis morbidity and mortality. Am J Kidney Dis. 1994;24(6): 1019-1032.
7. Hoenich NA. Platelet and leucocyte behaviour during haemodialysis. Contrib Nephrol. 1999;125:120-132.
8. Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young IS. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem. 1995;41(8 Pt 1):1135-1138.
9. Peuchant E, Carbonneau MA, Dubourg L, et al. Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamins A, E, and iron status. Free Radic Biol Med. 1994;16(3):339-346.
10. Hultqvist M, Hegbrant J, Nilsson-Thorell C, et al. Plasma concentrations of vitamin C, vitamin E and/or malondialdehyde as markers of oxygen free radical production during hemodialysis. Clin Nephrol. 1997;47(1):37-46.
11. Westhuyzen J, Saltissi D, Healy H. Oxidation of low density lipoprotein in hemodialysis patients: effect of dialysis and comparison with matched controls. Atherosclerosis. 1997;129(2): 199-205.
12. Loughrey CM, Young IS, McEneny J, et al. Oxidation of low density lipoprotein in patients on regular haemodialysis. Atherosclerosis. 1994;110(2):185-193.
13. Sutherland WH, Walker RJ, Ball MJ, Stapley SA, Robertson MC. Oxidation of low density lipoproteins from patients with renal failure or renal transplants. Kidney Int. 1995;48(1): 227-236.
14. Tsumura M, Kinouchi T, Ono S, Nakajima T, Komoda T. Serum lipid metabolism abnormalities and change in lipoprotein contents in patients with advanced-stage renal disease. Clin Chim Acta. 2001;314(1-2):27-37.
15. Jialal I, Fuller CJ. Effect of vitamin E, vitamin C and betacarotene on LDL oxidation and atherosclerosis. Can J Cardiol. 1995;11 Suppl G:97G-103G.
16. Jialal I, Fuller CJ, Huet BA. The effect of alpha-tocopherol supplementation on LDL oxidation. A dose-response study. Arterioscler Thromb Vasc Biol. 1995;15(2):190-198.
17. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun. 1989;6(1):67-75.
18. Cheung AK, Wu LL, Kablitz C, Leypoldt JK. Atherogenic lipids and lipoproteins in hemodialysis patients. Am J Kidney Dis. 1993;22(2):271-276.
19. Königer M, Quaschning T, Wanner C, Schollmeyer P, Krämer-Guth A. Abnormalities in lipoprotein metabolism in hemodialysis patients. Kidney Int Suppl. 1999;71:S248-S250.
20. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med. 1993;94(4):350-356.
21. Kronenberg F, Ikewaki K, Schaefer JR, König P, Dieplinger H. Kinetic studies of atherogenic lipoproteins in hemodialysis patients: do they tell us more about their pathology? Semin Dial. 2007;20(6):554-560.
22. Van Tits L, De Graaf J, Hak-Lemmers H, et al. Increased levels of low-density lipoprotein oxidation in patients with familial hypercholesterolemia and in end-stage renal disease patients on hemodialysis. Lab Invest. 2003;83(1):13-21.
23. Jurek A, Turyna B, Kubit P, Klein A. LDL susceptibility to oxidation and HDL antioxidant capacity in patients with renal failure. Clin Biochem. 2006;39(1):19-27.
24. Baldi S, Frascerra S, Ferrannini E, Natali A. LDL resistance to oxidation: effects of lipid phenotype, autologous HDL and alanine. Clin Chim Acta. 2007;379(1-2):95-100.
25. Callow J, Samra JS, Frayn KN. Effect of infusion of a triacylglycerol emulsion on low-density lipoprotein composition and oxidizability. Atherosclerosis. 1998;137(1):115-123.
26. Visioli F, Bordone R, Perugini C, Bagnati M, Cau C, Bellomo G. The kinetics of copper-induced LDL oxidation depend upon its lipid composition and antioxidant content. Biochem Biophys Res Commun. 2000;268(3):818-822.
27. de Man FH, Jonkers IJ, Schwedhelm E, et al. Normal oxidative stress and enhanced lipoprotein resistance to in vitro oxidation in hypertriglyceridemia: effects of bezafibrate therapy. Arterioscler Thromb Vasc Biol. 2000;20(11):2434-2440.
28. Bossola M, Tazza L, Luciani G, Tortorelli A, Tsimikas S. OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients. J Nephrol. 2011; 24(5):581-588.
29. Islam KN, O'Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis. 2000;150(1):217-224.
30. Ujhelyi L, Balla G, Jeney V, et al. Hemodialysis reduces inhibitory effect of plasma ultrafiltrate on LDL oxidation and subsequent endothelial reactions. Kidney Int. 2006;69(1):144-151.
31. Neuzil J, Weber C, Kontush A. The role of vitamin E in atherogenesis: linking the chemical, biological and clinical aspects of the disease. Atherosclerosis. 2001;157(2):257-283.